Growth rate-corrected (GR) dose-response metric signatures across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 3 of 4: Median, upper quartile, and lower quartile GR metrics per perturbagen. - Dataset (ID:20270)
Download: Excel (XLSX), Comma-separated (CSV)
Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | GR50 lower quartile | GR50 median | GR50 upper quartile | GRmax lower quartile | GRmax median | GRmax upper quartile | GRinf lower quartile | GRinf median | GRinf upper quartile | Hill Coefficient lower quartile | Hill Coefficient median | Hill Coefficient upper quartile | GR_AOC lower quartile | GR_AOC median | GR_AOC upper quartile | GEC50 lower quartile | GEC50 median | GEC50 upper quartile |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 36.5873 | 68.4588 | 100.0000 | -0.7737 | -0.2023 | 0.2203 | -0.7439 | -0.3900 | 0.2345 | 0.6570 | 1.9429 | 3.4993 | 0.1339 | 0.2188 | 0.2978 | 54.8881 | 71.4700 | 100.0000 | |
Nilotinib | ABL | nRTK | 100.0000 | 100.0000 | 100.0000 | 0.7849 | 0.9109 | 1.0055 | 0.7841 | 0.9109 | 1.0055 | 0.0000 | 0.0000 | 0.7234 | 0.0029 | 0.0487 | 0.0775 | 73.6076 | 100.0000 | 100.0000 | |
ZM-447439 | AURK | AURK | 3.5193 | 19.1991 | 100.0000 | -0.0403 | 0.4141 | 0.5578 | -0.1176 | 0.3301 | 0.5652 | 0.5578 | 1.0337 | 2.9596 | 0.1428 | 0.2012 | 0.3024 | 0.6732 | 2.5837 | 16.4745 | |
Purvalanol A | CDK1 | CDK | 25.2896 | 54.7310 | 100.0000 | 0.0757 | 0.5333 | 0.7416 | -0.0675 | 0.5068 | 0.7450 | 1.0817 | 2.5000 | 4.2404 | 0.0335 | 0.0774 | 0.1767 | 18.1854 | 35.4887 | 52.3768 | |
ICRF-193 | TOP2 | TOP | 8.5852 | 100.0000 | 100.0000 | 0.3561 | 0.5910 | 0.6710 | 0.2252 | 0.4446 | 0.6698 | 0.1440 | 0.6745 | 1.5658 | 0.1152 | 0.1622 | 0.2393 | 0.3708 | 3.7956 | 100.0000 | |
5-DFUR | TYMS | TYMS | 68.5295 | 100.0000 | 100.0000 | -0.1871 | -0.0208 | 0.0399 | -0.5625 | -0.3158 | -0.1425 | 0.3943 | 0.5084 | 0.6195 | 0.2584 | 0.3100 | 0.3856 | 100.0000 | 100.0000 | 100.0000 | |
5-FU | TYMS | TYMS | 43.5628 | 98.8715 | 100.0000 | -0.6126 | -0.4736 | -0.0711 | -0.8532 | -0.6532 | -0.1200 | 0.5225 | 0.5967 | 0.7832 | 0.3295 | 0.4853 | 0.6100 | 100.0000 | 100.0000 | 100.0000 | |
Pemetrexed | TYMS/DHFR/GARFT | TYMS | 70.1583 | 100.0000 | 100.0000 | 0.5012 | 0.6411 | 0.8577 | 0.5144 | 0.6941 | 0.8649 | 0.0000 | 0.7943 | 1.8547 | 0.0614 | 0.1870 | 0.3357 | 0.9463 | 34.1832 | 100.0000 | |
Methotrexate | DHFR | Metabolism | 0.1850 | 100.0000 | 100.0000 | 0.3067 | 0.6372 | 0.9078 | 0.3672 | 0.5884 | 0.9117 | 0.0000 | 2.3582 | 4.5415 | 0.0328 | 0.2767 | 0.4502 | 0.0331 | 0.1737 | 100.0000 | |
Baicalein | Lipoxygenase | Metabolism | 41.6425 | 70.6950 | 100.0000 | -0.0508 | 0.2583 | 0.5386 | -0.5772 | 0.0203 | 0.4255 | 1.6411 | 2.5826 | 3.9209 | 0.0595 | 0.1090 | 0.1450 | 32.6213 | 62.3319 | 100.0000 | |
Disulfiram | Proteasome | Proteasome | 0.2148 | 13.4616 | 100.0000 | -0.6139 | 0.0054 | 0.4486 | -0.9836 | -0.0088 | 0.5061 | 0.2242 | 2.0208 | 4.9998 | 0.1469 | 0.2459 | 0.3654 | 0.1623 | 16.2617 | 100.0000 | |
(Z)-4-Hydroxytamoxifen | ESR1 | N/A | 38.2142 | 72.1652 | 100.0000 | -0.2149 | 0.3051 | 0.6418 | -0.8145 | -0.0997 | 0.5442 | 0.6236 | 1.8012 | 2.9451 | 0.0928 | 0.1395 | 0.2253 | 17.7725 | 43.7586 | 100.0000 | |
Ibandronate | FDPS | N/A | 49.3295 | 82.7741 | 100.0000 | -0.5209 | -0.1213 | 0.0387 | -0.7048 | -0.2169 | -0.0113 | 0.9599 | 1.4483 | 1.9155 | 0.2062 | 0.2750 | 0.3199 | 66.6332 | 98.6899 | 100.0000 | |
CGC-11047 | Polyamine analogue | N/A | 43.1451 | 85.4630 | 100.0000 | -0.8722 | -0.7234 | -0.2437 | -1.0000 | -0.9172 | -0.4365 | 0.4134 | 0.5735 | 1.1488 | 0.3172 | 0.3971 | 0.4905 | 94.6485 | 100.0000 | 100.0000 | |
Glycyl-H-1152 | ROCK2 | N/A | 7.8389 | 29.5632 | 100.0000 | 0.0725 | 0.4318 | 0.6407 | -0.4259 | 0.0666 | 0.6245 | 0.3449 | 0.9010 | 2.0476 | 0.0704 | 0.1476 | 0.1891 | 2.5420 | 16.8696 | 100.0000 |